Cervarix and Gardasil are the 2 vaccines to help in the prevention of cervical cancer caused by certain strands of HPV. Cervarix, created by Glaxo, Smith, Kline, has yet to be approved but has been recently submitted to the FDA for approval. Merck & Co., Gardasil, on the other hand, has been around for awhile and is already noticing a decline in sales of their HPV vaccine. The vaccine is given to females age 9 - 26, given 3 injections over a 6 month span.
Question is, is Cervarix too late to jump on the bandwagon? Once vaccinations are administered worldwide, it would make perfect sense to assume that the need for the drug would begin to diminish. And so an analyst at Jeffries International, Jeffrey Holford, has concluded as well when he stated "Glaxo is 3 to 4 years late into the market. They have lost the bulk of the opportunity in the U.S."
Only time will tell what is in store for these 2 companies. Though I must wish them the best of luck and give them thanks for helping to reduce the number of cervical cancer deaths.